Our study demonstrates that AT-II, a novel FXR agonist, can protect against NAFLD by addressing the interplay between FXR and ER stress, while AT-II therapy may help to avoid the negative effects of steroidal FXR agonists on lipid profiles. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.